Showing Results for
- Academic Journals (45)
Search Results
- 45
Academic Journals
- 45
- Search Terms:
- 1From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedIn 1995, during the annual meeting of The European Group for Blood & Marrow Transplantation (EBMT) held in Davos, Switzerland, the issues related to the differences underlying treatment approaches towards adult and...
- 2From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedViral infections remain a major cause of morbidity and mortality after pediatric hematopoietic stem cell transplantation. Adoptive transfer of donor-derived virus-specific T cells can reconstitute antiviral immunity in...
- 3From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedGvHD remains a source of significant morbidity and mortality in the setting of allogeneic haematopoietic SCT. Improving outcomes in stem cell transplant recipients requires additional therapeutic modalities for GvHD,...
- 4From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedThe use of G-CSF and GM-CSF has been shown to benefit patients undergoing autologous hematopoietic SCT (HSCT), mainly after autologous bone marrow transplantation. Their benefit in allogeneic transplant is not as...
- 5From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedFanconi anaemia (FA) is a rare genetic disease characterized by chromosomal instability, somatic abnormalities, marrow failure and cancer proness. The main cause of morbidity and mortality is bone marrow failure, which...
- 6From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedAcute graft-versus-host disease (GVHD) is one of the major complications of hematopoietic stem cell transplantation. Many variables including stem cell source, age of donor and recipient, preparative regimen and...
- 7From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedThe use of alternative hematopoietic stem cell (HSC) donors has been witnessing important progress, mainly due to: (i) better HLA matching at the allelic level between donor and recipient in unrelated HSC transplantation...
- 8From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedInvasive mycoses represent a rare but severe complication following hemopoietic SCT (HSCT) in children. Their incidence is related to the type of donor, being higher after allogeneic transplant, especially from...
- 9From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedThe main challenge for a pediatric hemato-oncologist today is to obtain a cure for the sick child with the minimum of treatment-related complications. Children on their way to achieving adulthood face many risks after...
- 10From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedBetween 1978 and 2006, the European Group for Blood and Marrow Transplantation registered 4098 high-dose therapy (HDT) procedures followed by stem cell rescue (SCR) (3974 autologous/124 allogeneic) in patients with...
- 11From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedGene therapy using autologous hematopoietic stem cells (HSC) that are corrected with the normal gene may have a beneficial effect on blood cell production or function, without the immunologic complications of allogeneic...
- 12From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedOver 50 years have passed since the original reports by Thomas et al. (1,2) on the use of hematopoietic stem-cell transplantation (HSCT) in children and adolescents. Since that time, there has been considerable progress...
- 13From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedAllogeneic hematopoietic SCT (HSCT) is an established treatment for some children with life-threatening hematological disease, immune deficiencies and inborn errors of metabolism. Despite advances in prevention and post...
- 14From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedChildhood histiocytoses comprise two main diseases, Langerhans cell histiocytosis (LCH) and hemophagocytic lymphohistiocytosis (HLH). LCH is a rare disorder with obscure pathogenesis. Data on clonality suggested...
- 15From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedAllogeneic hematopoietic SCT is well established as a potentially curative therapy for children and adults with both malignant and nonmalignant diseases. However, myeloablative SCT is associated with significant...
- 16From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedDuring the last 10 years, the number of alternative Haematopoietic stem cell transplantations (HSCTs) performed on children in Europe has increased significantly and has reached 61% of the allografts. In this paper, we...
- 17From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedUmbilical cord blood transplant (UCBT) is now used more frequently for transplanting children with high-risk malignancies. The advantages are the rapid availability of donor cells, the possibility of using HLA-mismatched...
- 18From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedMyeloablative chemotherapy with autologous hematopoietic progenitor cell rescue has been evaluated in the treatment of children and young adults with brain tumors for whom conventional therapy is either too toxic (for...
- 19From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedThe use of DLI can change chimerism and prevent rejection and relapse. However, the prerequisite for a successful use of this powerful and potentially harmful tool is a minimal burden with resting leukemia or in the case...
- 20From: Bone Marrow Transplantation. (Vol. 41, Issue 2) Peer-ReviewedOver the past 30 years, a significant improvement in the prognosis of localized osteosarcoma of the extremities has been observed. Despite these results, approximately 30-40% of patients will relapse, mostly within the...